Thiochroman derivative CH4986399, a new nonsteroidal estrogen receptor down-regulator, is effective in breast cancer models

Anticancer Research

Volumn 30, Issue 3, 2010, Pages 873-878

  Yoneya, Takaaki ^a   Taniguchi, Kenji ^a   Nakamura, Ryo ^a   Tsunenari, Toshiaki ^a   Ohizumi, Iwao ^b   Kanbe, Yoshitake ^c   Morikawa, Kazumi ^b   Kaiho, Shin Ichi ^a   Yamada Okabe, Hisafumi ^b  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b Fuji Gotemba Research Laboratories   (Japan)

^c Ukima Research Laboratories   (Japan)

Author keywords

Breast cancer; Nonsteroidal; Orally active; Selective estrogen receptor down regulator SERD

Indexed keywords

ACOLBIFENE; ANTINEOPLASTIC AGENT; ARZOXIFENE; CH 4986399; ESTROGEN RECEPTOR; FULVESTRANT; PIPENDOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; THIOCHROMAN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; DISEASE MODEL; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG STRUCTURE; ESTROGEN ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; XENOGRAFT;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; FEMALE; HUMANS; MICE; MICE, NUDE; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77951033352     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Adamo V, Iorfida M, Montalto E, Festa V, Garipoli C, Scimone A, Zangì M and Caristi N: Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients. Ann Oncol 18(Suppl 6): vi53-vi57, 2007.
2. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R and Buzdar A: Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20: 3386-3395, 2002.
3. Howell A, Robertson JFR, Quaresma Albano J, Achermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A and Morris C: Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20: 3396-3403, 2002.
4. Howell A, Robertson JFR, Abram P, Lichinister MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I and Osborne CK: Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22: 1605-1613, 2004.
5. Robertson JFR: Fulvestrant (Faslodex) - How to make a good drug better. Oncologist 12: 774-784, 2007.
6. Vergote I, Amant F, Leunen K, Van Gorp T, Berteloot P and Neven P: Metastatic breast cancer: sequencing hormonal therapy and positioning of fulvestrant. Int J Gynecol Cancer 16(Suppl 2): 524-526, 2006.
7. Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm A-V, Rasmussen LM, Riese DJ 2nd, de Cremoux P, Stenvang J and Lykkesfeldt AE: Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat 114: 263-275, 2009.
8. Connor CE, Norris JD, Broadwater G, Willson TM, Gottardis MM, Dewhirst MW and McDonnell DP: Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor. Cancer Res 61: 2917-2922, 2001.
9. Dardes RC, O'Regan RM, Gajdos C, Robinson SP, Bentrem D, De Los Reyes A and Jordan VC: Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo. Clin Cancer Res 8: 1995-2001, 2002.
10. Wittmann BM, Sherk A and McDonnell DP: Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators. Cancer Res 67: 9549-9560, 2007.
11. Kanbe Y, Kim M-H, Nishimoto M, Ohtake Y, Tsunenari T, Taniguchi K, Ohizumi I, Kaiho S, Nabuchi Y, Kawata S, Morikawa K, Jo J-C, Kwon H-A, Lim H-S and Kim H-Y: Discovery of thiochroman derivatives bearing a carboxy-containing side chain as orally active pure antiestrogens. Bioorg Med Chem Lett 16: 4090-4094, 2006.
12. Yoneya T, Taniguchi K, Tsunenari T, Saito H, Kanbe Y, Morikawa K and Yamada-Okabe H: Identification of a novel, orally bioavailable estrogen receptor down-regulator. Anticancer Drugs 16: 751-756, 2005.
13. Yoneya T, Tsunenari T, Taniguchi K, Kanbe Y, Morikawa K, Yamada-Okabe H, Lee Y-H, Lee, M-H and Kwon L-S: Effects of CH4893237, a new orally active, estrogen receptor down-regulator, on breast cancer xenograft models with low serum estrogen levels. Oncol Rep 21: 747-755, 2009.
14. Wakeling AE, Dukes M and Bowler J: A potent specific pure antiestrogen with clinical potential. Cancer Res 51: 3863-3873, 1991.
15. Gradisher WJ: Tamoxifen-What next? Oncologist 9: 378-384, 2004.
16. Ali S and Coombes RC: Endocrine-responsive breast cancer strategies for combating resistance. Nat Rev Cancer 2: 101-112, 2002.
17. Baumann CK and Castiglione-Gertsch M: Estrogen receptor modulators and down-regulators. Drugs 67: 2335-2353, 2007.
18. Bardy H, Desasi S, Gayo-Fung LM, Khammungkhune S, McKie JA, O'Leary E, Pascasio L, Sutherland MK, Anderson DW, Bhagwat SS and Stein B: Effects of SP500263, a novel, potent antiestrogen, on breast cancer cells and in xenograft models. Cancer Res 62: 1439-1442, 2002.